Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

ABSTRACT: This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.

DISEASE(S): Carcinoma,Sarcoma,Metastatic Castration Resistant Prostate Cancer,Triple Negative Breast Neoplasms,Colorectal Cancer,Urothelial Carcinoma,Triple-negative Breast Cancer,Pancreatic Cancer,Squamous Cell Carcinoma Of Head And Neck,Non-small Cell Lung Cancer,Carcinoma, Renal Cell,Gastroesophageal Cancer,Renal Cell Carcinoma,Cholangiocarcinoma,Hepatocellular Carcinoma

PROVIDER: 2296301 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Enterococcus faecium strain:1120

Project description:Enterococcus faecium strain:1120 Genome sequencing

| PRJNA267686 | ENA

Panicum virgatum cultivar:SWAG3-1120

Project description:Panicum virgatum exome capture - SWAG3-1120

| PRJNA446271 | ENA

Metarhizium robertsii strain:1120

Project description:Metarhizium robertsii strain:1120 Genome sequencing and assembly

| PRJNA357828 | ENA

A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer

Project description:This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-programmed cell death protein 1 (anti-PD1) antibody-activated autologous tumor-infiltrating lymphocytes (TILs) combined with adjuvant chemotherapy in participants with stage III colon cancer. Twenty participants were enrolled and anti-PD1 antibody-activated TILs was infused into participants after the final of adjuvant chemotherapy to assess the safety and 3-year disease-free survival.

| 2302069 | ecrin-mdr-crc

The immunocytokine PD1-IL2v overcomes resistance to tumor immunity, and synergizes with anti-PD-L1

Project description:Immunotherapies have shown remarkable, albeit tumor-selective therapeutic benefits in the clinic. Here we evaluated the effects of the immunocytokine PD1-IL2v in a mouse model of de novo pancreatic neuroendocrine cancer resistant to checkpoint and other immunotherapies. PD1-IL2v is a bi-specific molecule based on a bivalent PD-1 antibody, serving as a targeting moiety, fused to an immuno-stimulatory IL-2 variant (IL2v) to precisely deliver IL2v to PD-1+ T-cells in the tumor microenvironment. PD1-IL2v elicited dramatic infiltration by CD8 T cells, notably stem-like and effector memory T cells, resulting in tumor regression and enhanced survival in mice. Furthermore, combining anti-PD-L1 with PD1-IL2v sustained the response phase, improving therapeutic efficacy both by reprogramming immunosuppressive tumor-associated macrophages and tumor endothelial cells , and by enhancing TCR immune repertoire diversity. The data motivate consideration of clinical trials to evaluate the combination therapy of PD1-IL2v and anti-PD-L1, especially in immunotherapy-resistant tumors infiltrated with PD-1+ T stem-like CD8 T cells.

2023-01-10 | GSE197854 | GEO

Novel insights into redox-based mechanisms for auranofin- induced rapid cancer cell death

Project description:One of the significant features of cancer cells is a persistent pro-oxidative status. Therefore, compared to their normal counterparts, the malignant cells are generally more dependent on antioxidants for cell survival and more vulnerable to further oxidative insults via pharmacolog-ical interventions targeting cellular redox systems. This is the biological basis of oxidative stress- or redox-based anticancer strategies. Auranofin (AUF) is a promising repositioning anti-cancer molecule with a multifaceted mode of action that could be cancer cell type- or dose-dependent. Using triple-negative breast cancer cells, we evidenced that thioredoxin reduc-tase inhibition, the best-studied anticancer activity of AUF, is not sufficient to induce efficient cell death. Cytotoxic doses of AUF trigger rapid and global intracellular oxidative stress. Based on the indications from redox proteome data, we showed experimentally that AUF treatment triggered a dose-dependent S-phase arrest and disintegration of actin cytoskeleton structure. These findings on AUF-induced early effects should provide novel insights into the anticancer mechanisms of this promising molecule

2023-03-11 | PXD036558 | Pride

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Project description:This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.

| 2267503 | ecrin-mdr-crc

High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model

Project description:High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model

| PRJNA593511 | ENA

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

Project description:High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

| PRJNA593266 | ENA

SN-38, an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma

Project description:Anti-programmed cell death 1 (PD-1) therapy shows definite but modest activity in patients with advanced/metastatic HNSCC. Preliminary evidence suggests that SN-38, an activated form of irinotecan that activates the transcription factor FoxO3a, may suppress the expression of PD-L1 in breast and ovarian tumor models. Here, we explore the efficacy of SN-38 in combination with anti-PD1 for HNSCC treatment. In vitro, SN-38 enhances FoxO3a expression and reduces the expression of PD-L1 dose-dependently in HNSCC cells. Low dose SN-38 increases interferon- excretion by natural killer (NK) cells and promotes NK cell-mediated cytotoxicity of tumor cells. In vivo studies reveal that, at non-cytotoxic drug concentrations, SN-38 significantly enhances anti-PD-1 activity in suppressing murine tumor growth. An increased infiltration of CD8+ T cells and NK cells was found in the post-treatment tumors. RNA-seq analysis confirms that SN-38 promotes the enrichment of immune cells and biological function genes related to the immune response became abundant in SN-38 and anti-PD1 treated tumors. Thus, SN-38 is a potentially beneficial adjunct to checkpoint inhibitor therapy in HNSCC. Further studies to explore its mechanism of action and possible application are mandatory.

2023-01-11 | GSE222450 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data